Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 40

Results For "RIL"

1503 News Found

Alvotech and Advanz Pharma secure European nod for Gobivaz, first biosimilar to Simponi
Drug Approval | November 24, 2025

Alvotech and Advanz Pharma secure European nod for Gobivaz, first biosimilar to Simponi

Gobivaz is authorised for adults with rheumatoid arthritis (in combination with methotrexate), psoriatic arthritis (with or without methotrexate), axial spondyloarthritis, and ulcerative colitis


Merck’s two-drug HIV regimen hits phase 3 success
Clinical Trials | November 21, 2025

Merck’s two-drug HIV regimen hits phase 3 success

The study successfully met its primary endpoint, demonstrating similar rates of viral suppression for DOR/ISL compared to Biktarvy at 48 weeks


Sudeep Pharma eyes Rs. 895 crore fundraising from debut on bourses
News | November 19, 2025

Sudeep Pharma eyes Rs. 895 crore fundraising from debut on bourses

The issue comprises a fresh issue of Rs. 95 crore and targeting a total raise of around Rs. 895 crore


Indian pharma sector poised for a global leap beyond generics: K. Raja Bhanu, DG, PHARMEXCIL
News | November 17, 2025

Indian pharma sector poised for a global leap beyond generics: K. Raja Bhanu, DG, PHARMEXCIL

With US$ 30.46 billion in exports and robust manufacturing capabilities, the industry is poised to expand into high-value drugs while strengthening ESG and compliance standards


Pfizer completes up to $10 billion acquisition of Metsera
News | November 14, 2025

Pfizer completes up to $10 billion acquisition of Metsera

Acquisition brings highly differentiated clinical-stage obesity candidates with potential to reshape the treatment landscape


Terumo BCT and Santersus partner to advance blood purification therapy for sepsis
Technology | November 14, 2025

Terumo BCT and Santersus partner to advance blood purification therapy for sepsis

Sepsis is a life-threatening reaction to infection that overwhelms the body’s defenses


Biohaven disappointed as rare disease therapy faces FDA setback 'despite promising results'
Drug Approval | November 10, 2025

Biohaven disappointed as rare disease therapy faces FDA setback 'despite promising results'

The FDA setback highlights ongoing tensions between patient needs, regulatory processes, and the use of real-world evidence in evaluating treatments for rare diseases


Novo Nordisk India partners with Emcure to commercialise Poviztra in India
News | November 10, 2025

Novo Nordisk India partners with Emcure to commercialise Poviztra in India

Poviztra is a second brand of Wegovy